

Neutral



■ (08930) BUY ■ (69620) BUY

?

가 2000  
50  
가  
20.4% 2010 28.7%  
가  
가  
가

가 2003.4

가 2003.4 (LG ) FDA



# 목 차

Executive Summary	3
I. 가	4
II. 가	5
III.	8
1. 가 가	
2. 가	
IV.	11
1.	
2. 가	
3.	
V.	20
1. :	
2. :	
3. : 9%	
4.	
5.	
[ ]	26
1. (08930)	
2. (69620)	
1:	
2:	



I. 가

: (Neutral)

(Neutral)

가  
가 2002  
가  
가 50  
가

가 : 2003. 4

FDA

가

가  
가

가 01

PER 2000 8.9 2001 6.6 , 2002 6.2

가

LG


(LG )

6  
FDA

2003.4


가

[ 1 ]



:CYBOS2002,

[ 2 ]



:


II. 가

2000.8

2000.8

가

[ 3]



[ 1]

	(~2000.8 )	(2000.8 ~ )	
	,		
	가	가 ,	가 ,
		,	,
	가		가

99 53.2% 2001 62.8% 9.6%

2001 3 8 7

3,096 52% 가

( 가 )

가 )

( )

2000.8 2001


2001

( 가 ) 4 4 62.8%

99 9.6% 가 2001

14% 2.8% 가

[ 4 ]



가 50 46.3%가

가

가 . 99

16.2% 2001 21.6% 가  
가 . 가

. 2002 1~9 100  
33.3%

[ 2] ( : , .%)

	98	99	00	01
59	33,787	34,581	37,421	41,420
	65.7	64.2	60.5	56.7
26	7,389	8,706	11,790	15,811
	14.4	16.2	19.1	21.6
82	10,278	10,595	12,611	15,865
	20.0	19.7	20.4	21.7
167	51,454	53,881	61,821	73,096

가 가 가 가  
가 가 가 가

III.

1. 가 가

[ 3]

가	(가 )	가 가	11 1 가
가 가	(가 )	99 가 7	
가	(가 )	7 가 가	2001 가 가
	( )		가 ( )
가		8.7%, 3%	가 가 가

가 가

가 (1 ) 가 가 가  
가 가 가 가 가  
가 가 가 12 3 14,000 가  
가 7 가 가 가 가 가  
2,732 가 가 가 가 가  
가 가

가 ( 가 ) . 7 376  
 2 가  
 가 가 가 가  
 , 가 가 , , , , ,  
 . 7 , , , , , , , ,  
 376 , , , 3,601 .  
 가  
 가 가 .  
 가 가 .  
 가 .  
 가 8.7%, 3% .  
 가 11 15 , 가 가 .  
 가 가 가 , 가 가  
 가 가 가  
 가 가  
 ,

2. 가

50 가 41.6%

가 가 65 가

( 가 40 가 )

( 가 50 )

2000 20.4%

53.7%, 41.6%

96 25.9% 48.2% 50

가 , ,

50 2002 21.4% 2010


28.7% 가 2019 37.5% 가

[ 4] ( : , , ,%)

	1	1	1	1	1	1
0 - 9	14.4	12.6	13.9	8.1	20.2	137,176
10~19	14.8	3.7	5.7	2.0	5.7	54,900
20~29	17.5	5.2	9.8	1.9	7.0	79,651
30~39	18.1	9.2	13.5	2.8	11.8	106,413
40~49	14.8	15.7	15.5	3.6	24.6	149,328
50~59	9.3	20.4	14.7	5.1	51.0	225,606
60~64	3.9	11.2	8.4	6.6	67.0	310,512
65~69	2.9	9.6	7.6	7.7	75.5	368,674
70	4.3	12.5	10.8	6.9	68.0	359,939
	100.0	100.0	100.0	4.1	23.2	142,417

: 가  
: 01

[ 5] 50







2002.1~9 12% 30  
 15.5% 2001 02

가 가 . 2002  
 가 가 가

2002  
 02.9

가

[ 6] (02.9) ( : ,%)

1		678.4	51.4	16	377.4	7.5
2		904.5	42.8	17	473.6	7.1
3		365.7	42.0	18	364.1	6.7
4		305.9	36.6	19	344.9	4.5
5	SK	267.4	35.7	20	516.3	4.1
6		1,211.2	28.7	21	469.6	3.2
7		937.5	19.7	22	720.1	-1.2
8		537.6	17.7	23	370.8	-1.8
9		336.4	17.2	24	424.0	-3.1
10		317.5	15.2	25	266.6	-5.5
11		401.2	13.0	26	547.2	-9.5
12		1,412.8	11.8	27	296.6	-11.3
13		598.1	11.2	28	265.0	-11.6
14		377.6	10.8	29	339.4	-20.4
15		543.0	8.5	30	275.7	-22.0
					15,246.3	15.5

: UB care,  
 :

11 (946.2 )

5 (482 )

[ 7] ( : , %)

	1				1		
	103.0	20.1	39.9		114.5	67.2	44.6
	44.8	191.2	-16.2		78.6	1,919.31	596.5
	60.9	-14.1	-16.2		136.4	100.7	75.4
	217.5	44.0	15.0		85.2	51.5	30.8
	151.5	-6.6	-34.4		113.0	14.4	4.4
	107.7	37.2	38.5		80.0	10.5	26.6
	91.0	-15.6	-35.6		69.5	4.0	1.7
	74.0	-1.2	-14.8		75.0	7.5	-6.3
	71.0	-48.7	-82.2		198.4	-26.9	-25.8
	66.8	48.4	39.4	가	104.4	55.8	49.1
	60.2	49.9	39.3		53.2	-	-
	55.8	141.5	-10.2		310.3	86.2	65.2
	50.5	-8.6	-15.6		85.5	5.2	2.2
	48.9	-	-		79.2	-17.5	-28.3
	79.3	25.7	15.4		79.0	16.3	5.8
	66.0	15.8	28.0		71.2	21.9	10.3
	56.9	84.7	41.0		130.1	282.1	48.1
	57.6	57.0	26.1		118.7	15.4	29.8
가	51.2	3.3	-13.5		107.5	9.1	4.6
	74.4	-11.6	-15.5		71.8	32.7	17.9
	52.8	-2.6	9.4		53.9	-9.4	-29.1
	64.3	3.7	-13.6		144.3	5.3	-1.3
	114.8	-11.4	-11.4		47.2	-14.1	-1.8
	76.7	-5.5	4.5		52.9	7.3	5.2

: UB care,


: 02.9

가 , 1 02.9 1

2. 가

( )  
 ( ) 30  
 92.2% . 가 ( ,  
 ) 11.9% , , 가 8.6%  
 . 가 , 7.6%, 7.2%  
 14.8% 2.3%, 2.2%  
 19.3%가 가  
 가 5.2%,  
 4.5%, 2.8%, 1.7% , 1.7% 15.9%  
 . 12%  
 1.3% 가


[ 6]



: UB care,

2002.9 12%  
 20 13.1% . ( ) , [247]  
 , [399] , [396] , [131]  
 [214] [218] , [217]  
 . [131]  
 . [239] 32.1% (56.5%)  
 )

[ 7]



: UB care,

40 가 가  
 가 가 , , 40  
 가 . 40 가

[ 8] ( : %)

						2000	2005	2009
10	0.0	0.0	0.0	0.0	0.0	14.4	12.4	11.0
10~19	0.1	0.1	0.1	0.2	0.1	14.8	13.6	13.6
20~29	0.4	0.4	0.4	0.5	0.6	17.5	15.8	14.3
30~39	2.5	2.8	2.3	3.6	3.9	18.1	17.7	16.6
40~49	12.8	13.6	11.3	14.9	16.6	14.8	16.9	16.9
50~59	24.8	25.0	23.7	28.5	27.6	9.3	10.7	12.9
60~69	34.0	33.3	35.1	34.3	33.6	6.8	7.4	7.9
70	25.4	24.7	27.1	18.0	17.6	4.3	5.5	6.8

: UB care, ,

3.

가 1

2002.1~9

가 945.0

1

가

(

),

, LG

[ 9]

(02.1~02.9 )

( : , %)

1		945.0	3.7	53		74.4 0.3
2		310.3	1.2	54		74.0 0.3
3		293.5	1.1	55		72.7 0.3
4		232.7	0.9	56		71.8 0.3
5		217.5	0.9	57		71.7 0.3
6		208.8	0.8	58		71.2 0.3
7		205.5	0.8	59		71.2 0.3
8		198.4	0.8	60		71.0 0.3
9		155.1	0.6	61		70.1 0.3
10		154.3	0.6	62		69.5 0.3
11		151.5	0.6	63	SK	67.1 0.3
12		148.3	0.6	64		66.8 0.3
13		148.1	0.6	65		66.1 0.3
14		144.3	0.6	66		66.0 0.3
15		136.4	0.5	67		66.0 0.3
16		130.1	0.5	68		65.7 0.3
17		122.6	0.5	69		65.0 0.3
18		121.0	0.5	70		64.3 0.3
19		118.7	0.5	71		63.5 0.2
20		114.8	0.4	72		61.7 0.2
21		114.5	0.4	73		60.9 0.2
22		113.7	0.4	74		60.2 0.2
23		113.0	0.4	75		60.2 0.2
24		107.7	0.4	76		59.4 0.2
25		107.5	0.4	77		58.2 0.2
26		106.4	0.4	78		57.6 0.2
27	가	104.4	0.4	79		56.9 0.236

28		103.7	0.4	80		56.9	0.2
29		103	0.4	81		56.4	0.2
30		95.1	0.4	82		55.9	0.2
31		94.6	0.4	83		55.8	0.2
32		94.1	0.4	84		55.4	0.2
33		92.8	0.4	85		54.9	0.2
34		92.8	0.4	86		54.3	0.2
35		92.2	0.4	87		53.9	0.2
36		91	0.4	88		53.2	0.2
37		87.7	0.3	89		52.9	0.2
38	SK	85.7	0.3	90		52.8	0.2
39		85.6	0.3	91	가	51.2	0.2
40		85.5	0.3	92		50.5	0.2
41		85.2	0.3	93		48.9	0.2
42		83.2	0.3	94		47.6	0.2
43		81.1	0.3	95		47.2	0.2
44		80	0.3	96		47.1	0.2
45		79.3	0.3	97		46.3	0.2
46		79.2	0.3	98		46.1	0.2
47		79.0	0.3	99		45.6	0.2
48		78.6	0.3	100		44.8	0.2
49		76.8	0.3			10,037.6	39.2
50		76.7	0.3			15,548.1	60.8
51		75.0	0.3			25,585.7	100.0
52	SK	74.8	0.3				

: UB care,

가 1

2002.1~9 (1 ~30 )

, LG

1

2002.1~9 (30 ~60 )

가

2002.1~9

(60 ~100 )

,

,

,

,


.

V.


1. :

2003 12.6%  
 ( ) 가 ( )  
 가 02.3 5 6 1  
 28.1% 가 가  
 가 02.3 가 4 46  
 2.7% 가  
 2002 13.1%(01 14.0%) 가  
 2003 가 가 가  
 가 , 가 가 12.1%

[ 8]




[ 9]



[ 10]



[ 11]



가

가 63.6%

가

가  
가

가

가

[ 10]

( : ,%)

	1.8	0.0		211.5	21.9
	2.5	0.3		48.9	5.1
	36.2	3.8		272.8	28.3
	63.3	6.6		43.3	4.5
	17.3	1.8		36.8	3.8
	121.0	12.6		613.2	63.6
	30.9	3.2		82.2	8.5
	7.7	0.8		10.1	1.0
	5.6	0.6		45.4	4.7
	11.1	1.2		11.4	1.2
	24.9	2.6		149.1	15.5
	80.3	8.3		963.8	100.0

가

2. :

가

GDP , 가

GDP 가 03 . 02

3.5%

가 4.1%

25 2001 19.7%

2.8%


가 7.1% (308 330

가


가

가

[ 12]



[ 13]



[ 11]	(01 )	( : %)
		2001
1		329 2,055.0 9.2
2		316 357.1 17.0
3		114 270.9 15.9
4		264 261.6 2.6
5		233 239.0 42.0
6		233 238.8 -1.8
7		329 234.7 -19.9
8	6 5 0 MG	114 211.7 76.8
9	SK	264 210.8 30.1
10		234 202.7 911.4
11	5 0 MG	392 162.4 19.5
12		231 159.8 12.0
13	6 0 0	141 153.9 3.7
14		264 149.9 12.1
15		329 140.3 -2.8
16	( C Z L )	264 135.1 1.3
17		316 134.5 42.6
18	( )	314 131.6 114.8
19		114 127.4 3.7
20		316 127.0 124.5
21		219 121.1 49.8
22		222 119.8 17.8
23	( )	611 114.1 4.6
24		314 112.6 383.4
25		329 107.9 40.9
		6,280.0 19.7

3. : 9%

02 13.1%, 3.5%  
 9.5% 03 12.1%, 4.1%  
 9.3%

4.

가

02 12  
36

가

[ 12]

	가	02.9	36
02.2			
02.3	가		
02.4			
02.5			
02.8		가가 1,017	
02.9		가	가
02.10			가


:

5.


2003

5 ( , , , )  
 2002 9.9% 가 16.4% 가  
 . 03 02 9.8% 가  
 2003 가 가  
 (13.0%)

[ 14]



[ 15]



02 3 12.4% 가, 10.3% 가  
 3 12.4%, 5.8%, 10.3% 가  
 가 가가  
 가

[ 13] 02 3 ( : ,%)

4,072.8	9.1	631.8	8.2	453.1	10.1	319.9	14.6
2,009.4	5.9	303.7	1.0	187.8	5.6	110.8	3.8
1,628.5	25.9	243.2	7.3	199.6	36.6	142.3	34.5
448.4	12.9	129.5	20.3	111.1	3.5	71.0	-1.7
543.9	26.1	101.5	18.3	88.2	45.4	61.8	32.1
2,068.7	6.7	300.1	4.2	495.2	8.6	326.5	7.8
1,275.2	24.3	196.5	-6.1	194.1	-6.7	130.6	3.3
12,046.9	12.4	1,906.2	5.8	1,729.2	10.3	1,163.0	11.8

(08930)

BUY

가 : 28,500

가 2002. 11. 19 가 (19,900 )

	( )	( )	( )	( )	EPS ( )	ROE (%)	PER ( )	EV/EBITDA ( )
00.12	1,491.0	220.2	135.1	114.3	1,775	13.2	11.2	5.1
01.12	1,847.2	320.4	253.1	191.3	2,838	18.4	7.0	3.4
02.12F	2,305.0	373.5	316.6	237.4	3,522	18.3	5.7	2.9
03.12F	2,706.3	434.8	394.8	296.1	4,391	19.3	4.5	2.1

>>

>>

5

>>

가

85

97

6,300

2007

80~90

01

27%

4

5

79

가

가

가

(BUY)

가

PER

2000

2001

가

PER

2000

26.2%, 2001 5.7%

가 2003

EPS 4,391

PER 5.6

15.9%

28,500

가

( : ,%)				
	00	01	02F	03F
	1,491.0	1,847.2	2,305.0	2,706.3
가	29.8	23.9	24.8	17.4
가	794.8	900.3	1,072.7	1,261.9
가	53.3	48.7	46.5	46.6
가	14.5	13.3	19.2	17.6
	301.1	342.6	394.4	497.9
	44.0	62.6	69.1	76.1
	138.7	155.0	179.9	195.0
( 가 )	17.0	27.2	39.0	39.7
	696.2	946.9	1,232.2	1,444.4
	46.7	51.3	53.5	53.4
가	53.1	36.0	30.1	17.2
	476.0	626.5	858.7	1,009.6
	31.9	33.9	37.3	37.3
가	53.8	31.6	37.1	17.6
	192.5	264.4	365.5	427.8
	134.9	194.5	261.1	311.3
	116.7	111.9	160.3	191.7
	220.2	320.4	373.5	434.8
가	14.8	17.3	16.2	16.1
가	51.8	45.5	16.6	16.4
	42.8	73.6	68.0	68.9
	2.9	4.0	2.9	2.5
가	-7.8	71.8	-7.6	1.3
	10.9	13.8	10.8	8.9
	127.9	140.9	124.9	108.8
	8.6	7.6	5.4	4.0
가	-1.7	10.1	-11.4	-12.9
	100.4	98.4	80.4	61.4
( )	-85.1	-67.3	-56.9	-40.0
	135.1	253.1	316.6	394.8
	9.1	13.7	13.7	14.6
가	120.2	87.3	25.1	24.7
	0.0	0.0	0.0	0.0
	0.0	0.0	0.0	0.0
	135.1	253.1	316.6	394.8
	20.9	61.8	79.1	98.7
	0.2	0.2	0.3	0.3
	114.3	191.3	237.4	296.1
	7.7	10.4	10.3	10.9
가	111.9	67.4	24.1	24.7

( : ,%)				
	00	01	02F	03F
	1,404.3	1,388.9	1,466.6	1,618.5
	214.5	186.6	89.0	109.1
	823.8	925.0	1,045.2	1,128.8
	222.1	163.3	203.8	239.3
	933.9	1,173.2	1,210.1	1,261.9
	333.1	508.9	521.2	533.5
	487.3	532.7	559.7	601.6
	2,338.3	2,562.1	2,676.7	2,880.4
	848.8	803.7	842.4	820.4
	147.5	110.2	137.5	161.4
	252.5	131.1	261.0	270.0
	253.3	302.7	181.6	100.5
	602.6	563.5	434.8	397.0
	468.3	383.8	202.2	101.7
	134.2	179.7	232.6	295.3
	1,451.4	1,367.3	1,277.1	1,217.4
	160.9	168.6	168.6	168.6
	305.5	305.1	305.1	305.1
	380.5	542.9	747.6	1011
	40.0	178.3	178.3	178.3
	886.9	1,194.8	1,399.6	1,663.0
+	2,338.3	2,562.1	2,676.7	2,880.4
( : )				
	00	01	02F	03F
	114.3	191.3	237.4	296.1
가	33.2	45.9	48.0	49.7
	-385.2	20.1	-193.4	-134.7
가	110.7	129.4	168.3	136.6
가	48.0	-54.6	40.5	35.5
가	52.4	-37.3	27.3	23.9
	77.5	81.1	90.9	105.8
	-160.2	338.5	183	316.9
가	156.3	90.2	75.0	91.5
가	25.8	3.1	0.0	0.0
	-47.4	110.5	0.0	0.0
	-134.6	-203.8	-75.0	-91.5
	6.7	7.7	32.7	32.7
	90.0	-118.5	129.8	9.0
	-32.8	-324.7	-3.5	-1.6
	198.4	279.7	-299.1	-180
	84.8	0.0	0.0	0.0
	-14.0	8.6	0.0	0.0
	319.7	-162.5	-205.5	-205.3
가	24.9	-27.9	-97.6	20.0
	189.6	214.5	186.6	89.0
	214.5	186.6	89.0	109.1

(69620)

BUY

가: 23,200

가 2002.11.19 가 (14,350 ), 03.3

	( )	( )	( )	( )	EPS ( )	ROE (%)	PER ( )	EV/EBITDA ( )
02.3								
03.3F	1,361	134	182	136	1,380	7.3	10.4	1.6
04.3F	2,993	619	601	450	4,559	24.4	3.1	0.4
05.3F	3,517	700	664	498	5,039	22.1	2.8	-0.1

- >> 1
- >> 11
- >>

2002.11.1

80%가

13~20%

가 15%

3%

1

11

02.2 가 6 40

가 04.3 EPS

4,559 PER 5.1 23,200

가(11/19 가 14,350 ) 60% 가

'BUY'

( : ,%)				( : ,%)				
	02.3	03.3F	04.3F	05.3F	0 2.3	03.3F	04.3F	05.3F
		1,361	2,993	3,517		1,440	1,917	2,384
가			-	18		368	531	864
가		728	1,457	1,749		655	707	757
가		53	49	50		168	369	434
가			-	20		983	1,036	1,087
		269	958	1,107		304	316	328
		57	63	70		659	701	741
		211	229	249		2,422	2,953	3,471
( 가 )		34	34	34		422	511	530
		634	1,536	1,768		138	138	138
		47	51	50		1	1	1
가			-	15		2	51	51
		499	917	1,069		349	407	476
		37	31	30		211	211	210
가			-	17		137	196	265
		263	469	549		771	918	1,006
		121	235	273		247	247	247
		75	167	199		949	949	949
						577	960	1,390
		134	619	700		-121	-121	-121
		10	21	20		1,652	2,035	2,465
가			-	13	+	2,422	2,953	3,471
		93	97	102				
		7	3	3		136	450	498
가			-	5	가	48	50	51
		11	9	8		-59	-282	-122
					가	31	61	57
		46	115	138	가	-107	201	65
		3	4	4	가	0	0	0
가			-	19		-370	57	64
		24	26	29		-244	275	491
( )		47	-19	-36	가	-273	92	92
		182	601	664	가	-103	0	0
		13	20	19		-170	1	-1
가			-	11		546	-93	-90
		0	0	0		68	68	68
		0	0	0		0	0	0
		0	0	0		-5	-2	-1
		182	601	664		0	50	0
		45	150	166		-104	0	0
		25	25	25		0	0	0
		136	450	498		-177	-19	-68
		10	15	14	가	125	163	333
가			-	11		243	368	531
						368	531	864

<< 1 >>

02.9

76.6%

가

[ 14] ( : , %)

			1
	876.6	76.6	102.9
	113.7	48.6	-2.3
	205.5	140.2	250.9
	76.8	-0.9	-27.4
	55.9	60.7	77.2
	59.4	145.1	323.7
	92.8	179.7	324.7
	34.0	50.5	119.2

: UB care,

: 02.9

가 , 1 02.9 1

02.9

58.8%

( )가

(

)가

가

[ 15] ( : , %)

			1
	408.3	58.8	36.4
	122.6	95.5	42.5
	52.9	7.3	5.2
	57.6	57.0	26.1

: UB care,

: 02.9

가 , 1 02.9 1

가

02.9 42.4%

[ 16] [396] ( : , %)

	1	2	3
	1,012.4	42.4	30.4
	310.3	86.2	65.2
	107.7	37.2	38.5
	87.7	7.9	3.4
	79.0	16.3	5.8
	56.9	36.7	23.6

: UB care,

: 02.9

가 , 1 02.9 1

02.9 40.9% 가 02.9  
135.3% 가 . 2002

[ 17] [131] ( : , %)

	1	2	3
	622.9	40.9	135.3
	66.0	88.3	9.4
	46.1	83.4	374.6
	32.3	43.3	30.7
	31.8	22.9	163.8
	23.8	16.2	13.8
0.1	34.1	141.4	439.9
	28.5	28.5	251.5
	12.9	23.0	43.9

: UB care,

: 02.9

가 , 1 02.9 1

33.4%

MSD

가

[ 18] [214]

( : , %)

			1
	1,847.7	33.4	32.3
	154.3	30.5	11.9
	103.0	20.1	39.9
	94.6	96.9	52
	106.4	44.2	45.3
	72.7	111.2	118.5
	70.1	3.1	-14.6
	71.2	21.9	10.3
8mg	43.0	124.7	89.7
2mg	39.3	14.5	15.9
	43.4	21.6	3.6
	37.6	14.2	18.0

: UB care,

: 02.9

가 , 1 02.9 1

32.1% (56.5% )  
 가 ,  
 ,  
 가  
 2 가

[ 19] [239] ( : , %)

		1		
		1,146.4	32.1	22.5
가	50mg	104.4	55.8	49.1
		94.1	0.1	-12.1
	SK	85.7	11.1	-3.3
		78.6	1,919.3	1,596.5
		64.3	3.7	-13.6
		43.2	28.8	-36.6
		33.3	-6.7	-14.8
		28.1	-7.6	-13.1
		18.8	-70.1	-95.5

: UB care,  
 : 02.9 가 , 1 02.9 1

가

2002.9 27.7% 가

[ 20] [220] ( : , %)

		1		
		1,939.0	27.7	17.3
		945.0	28.0	20.2
		144.3	5.3	-1.3
		85.5	5.2	2.2
		79.3	25.7	15.4
		61.7	11.0	-1.0
		85.2	51.5	30.8

: UB care,  
 : 02.9 가 , 1 02.9 1

LG

2002.9 22.2%

LG

LG

[ 21] [217] ( : , %)

		1		
		585.3	22.2	20.8
		148.1	28.3	34.2
	LG	136.4	100.7	75.4
		47.6	4.5	10.5
		25.0	28.3	18.7
4mg		29.1	28.6	-2.8
		19.5	0.0	-3.6
10mg		18.5	-13.2	-33.5

: UB care,  
: 02.9 가 , 1 02.9 1

2002.9 14%

9

가

가 , 가 .

[ 22] [232] ( : , %)

		1		
		1,318.2	14.0	-1.6
		103.7	-17.0	-31.5
		95.1	6.7	-3.7
		75.0	7.5	-6.3
		55.8	141.5	-10.2
가		43.4	-18.6	-32.0
		41.3	67.8	27.6
		38.8	32.2	-20.0
가		36.2	147.1	36.5
		39.1	-8.2	19.8
		42.8	9.8	-93.1

: UB care,  
: 02.9 가 , 1 02.9 1

가

2002.9 12%

가

[ 23] [395] ( : , %)

			1
	458.9	12.0	40.5
	118.7	15.4	29.8
	37.1	-14.5	23.9
	31.3	-24.6	12.9

: UB care,

: 02.9 가 , 1 02.9 1

가

2002.9 10.1%

가

가

B  
B

. LG

[ 24] [391] ( : , %)

			1
	460.3	10.1	-1.5
	148.3	1.7	-13.9
	42.4	39.7	9.7
	39.1	35.8	23.2
	25.7	-13.1	-33.3
가	51.2	3.3	-13.5
	18.4	42.3	33.6

: UB care,

: 02.9 가 , 1 02.9 1

2002.9 9%

[ 25] [237] ( : , %)

			1
	438.8	9.0	-0.4
	50.5	-8.6	-15.6
	36.7	-3.2	-12.6
	71.8	32.7	17.9

: UB care,

: 02.9

가 , 1 02.9 1

2002.9 9%

[ 26] [234] ( : , %)

			1
	716.9	9.0	-1.1
	113.0	14.4	4.4
	33.5	-15.1	6.8
	29.7	529.2	733.2
	20.9	3.8	-27.9

: UB care,

: 02.9

가 , 1 02.9 1

2

2002.9 5.4%

[ 27] [629] ( : , %)

1			
	1,413.4	5.4	7.1
	293.5	-7.6	-14.6
	217.5	44.0	15.0
	130.1	282.1	48.1
	81.1	-23.9	1.2
	54.9	-14.4	6.6
	44.3	0.3	13.8
	40.1	19.1	68.3

: UB care,

: 02.9 가 , 1 02.9 1

가

2002.9 4.2%

가 가

가

가

[ 28] [619] ( : , %)

1			
	3,036.3	4.2	8.4
	198.4	-26.9	-25.8
	232.7	32.0	27.8
	107.5	9.1	4.6
	76.7	-5.5	4.5
	80.0	10.5	26.6
	79.2	-17.5	-28.3
	71.7	81.7	-8.9
	44.4	37.8	-7.4
	65.7	25.7	-30.2
	63.5	1.0	-17.0
	66.0	15.8	28.0

: UB care,

: 02.9 가 , 1 02.9 1

2002.9 3.7%

[ 29] [115] ( : , %)

			1
	2,189.1	3.7	1.7
	208.8	9.9	8.5
	151.5	-6.6	-34.4
	114.8	-11.4	-11.4
	66.1	21.9	6.7
	60.9	-14.1	-16.2
	60.2	7.4	-12.9
	41.8	2.8	-15.7

: UB care,  
: 02.9 가 , 1 02.9 1

2002.9 1.1%

가 67.2%

[ 30] [222] ( : , %)

			1
	1,422.8	1.1	-2.5
	114.5	67.2	44.6
	91.0	-15.6	-35.6
	69.5	4.0	1.7
	53.9	-9.4	-29.1
	58.2	90.6	88.7
	74.4	-11.6	-15.5
	52.8	-2.6	9.4

: UB care,  
: 02.9 가 , 1 02.9 1

2002.9 0.6%

[ 31] [141] ( : , %)

			1
	415.3	0.6	2.5
	37.6	16.2	31.5
	30.6	-5.2	-15.5
	37.4	31.7	23.2
	25.7	-24.7	-28.5
	20.6	-9.3	-1.9

: UB care,

: 02.9

가 , 1 02.9 1

2002.9 48.7%가

가

[ 32] [233] ( : , %)

			1
	441.6	-56.5	-82.9
	71.0	-48.7	-82.2
	18.9	-36.2	-65.3
	14.5	-69.7	-80.4
	13.8	-68.8	-95.8
	12.9	-58.1	-75.8

: UB care,

: 02.9

가 , 1 02.9 1

<< 2 >>

[ 33] (2001 ) ( : , , ,%)

		가			가			
		12,541	8.1	68.1	153.3	20.2	7.5	11.8
		10,812	7.0	105.0	90.0	14.4	3.8	10.2
		10,066	6.5	83.2	99.0	22.2	6.2	15.0
		8,494	5.5	33.1	235.6	8.8	6.9	1.8
		7,156	4.6	58.1	106.5	15.6	10.8	4.4
		6,776	4.4	43.0	134.3	17.4	4.3	12.6
		5,488	3.6	26.2	166.4	25.8	17.8	6.8
		5,274	3.4	53.8	77.0	27.2	14.9	10.7
		4,688	3.0	57.2	65.4	25.3	6.8	17.3
		4,241	2.7	67.4	51.4	22.4	10.5	10.8
2		4,189	2.7	52.3	82.8	-3.3	2.3	-5.4
		4,057	2.6	31.5	115.3	11.8	11.1	0.7
		4,020	2.6	144.4	21.3	30.6	16.1	12.5
		3,655	2.4	57.6	49.3	28.5	17	9.9
		3,530	2.3	27.8	123.7	2.6	-4.1	7.0
		3,187	2.1	52.0	52.4	17.0	11.7	4.8
		3,182	2.1	32.8	86.4	12.2	5.4	6.5
		2,948	1.9	33.7	76.2	14.9	14.1	0.7
		2,572	1.7	365.9	5.8	20.6	10.4	9.2
		2,472	1.6	30.0	79.3	4.0	1.1	2.8
		2,164	1.4	49.6	40.4	8.1	2.9	5.0
		1,906	1.2	74.9	21.2	20.2	8.2	11.1
		1,902	1.2	69.9	20.1	35.2	4.0	29.9
		1,648	1.1	46.2	30.9	15.3	11.6	3.3
		1,521	1.0	168.4	7.8	15.6	8.9	6.1
25		118,488	76.7	50.9	1,991.80	17.0	9.3	7.1
		36,013	23.3	33.2	923.2	17.4	12.0	4.8
		154,501	100.0	45.3	2,915.2	17.1	10.1	6.3

: AIR

: 2

[ 34]

( : ,%)

		Sales			
Zoloft		2,153	17.2	13.9	( )
Paxil		2,124	16.9	17.5	( )
Prozac		1,994	15.9	-22.3	( )
Wellbutrin		1,186	9.5	39.4	
All Others		5,084	40.5	53.3	Others
<b>Total</b>		<b>12,541</b>	<b>100.0</b>	<b>20.2</b>	<b>Total</b>
Prilosec		3,999	37.0	-2.5	8,550 가 ( )
Prevacid		3,196	29.6	12.8	
Aciphex		720	6.7	93.5	Eisai
Ranitidine		708	6.5	2.5	,
Others		2,189	20.3	50.7	
<b>Total</b>		<b>10,812</b>	<b>100.0</b>	<b>14.4</b>	
Lipitor		4,518	44.9	22.3	
Zocor	CHOLESTEROL REDUCER	2,739	27.2	24.1	
Pravachol		1,420	14.1	18.0	
Tricor		278	2.8	75.0	
Others		1,112	11.0	13.6	
<b>Total</b>		<b>10,066</b>	<b>100.0</b>	<b>22.2</b>	
Zithromax		1,075	12.7	11.8	
Cipro		1,066	12.5	4.1	
Levaquin		897	10.6	19.1	Levofloxacin
Ceftin		466	5.5	2.2	Cefuroxime
Others		4,990	58.7	8.2	
<b>Total</b>		<b>8,494</b>	<b>100.0</b>	<b>8.8</b>	
Celebrex		2,387	33.4	18.4	/
Vioxx		2,026	28.3	33.5	MSD
Enbrel		595	8.3	18.9	
Naproxen*		323	4.5	12.5	
Others		1,825	25.5	-2.4	
<b>Total</b>		<b>7,156</b>	<b>100.0</b>	<b>15.6</b>	

	Sales			
Zestril	911	13.4	9.3	
Accupril	563	8.3	12.5	
Lotrel	538	7.9	52.1	
Prinivil	508	7.5	17.8	
Others	4,256	62.8	16.5	
<b>Total</b>	<b>6,776</b>	<b>100.0</b>	<b>17.4</b>	
Oxycontin	1,486	27.1	41.1	
Hydrocodone/Apap*	1,197	21.8	28.0	
Duragesic	530	9.7	50.2	
Propoxyphene - N/Apap*	477	8.7	4.2	
Others	1,798	32.8	15.1	
<b>Total</b>	<b>5,488</b>	<b>100.0</b>	<b>25.8</b>	
Glucophage	1,734	32.9	6.5	BMS
Actos	934	17.7	69.6	/BMS
Avandia	925	17.5	49.8	
Glyburide*	334	6.3	0.1	
Others	1,347	25.5	32.7	
<b>Total</b>	<b>5,274</b>	<b>100.0</b>	<b>27.2</b>	
Claritin	1,870	39.9	12.1	
Allegra	1,165	24.8	43.8	
Zyrtec	975	20.8	31.8	UCB
Claritin	376	8.0	25.9	
Others	303	6.5	33.9	
<b>Total</b>	<b>4,688</b>	<b>100.0</b>	<b>25.3</b>	
Neurontin	1,486	35.0	31.3	,
Depakote	731	17.2	- 3.6	
Topamax	393	9.3	78.8	Ortho - McNeil
Clonazepam*	367	8.7	4.5	
Others	1,264	29.8	26.0	
<b>Total</b>	<b>4,241</b>	<b>100.0</b>	<b>22.4</b>	

		Sales			
Norvasc	(CALCIUM )	1,767	42.2	10.6	
Verapamil		335	8.0	11.2	
Cartia		308	7.4	-7.1	
Tiazac		239	5.7	20.2	
Others		1,540	36.8	-19.0	
<b>Total</b>		<b>4,189</b>	<b>100.0</b>	<b>-3.3</b>	
Premarin		1,240	30.6	8.2	
Prempro		781	19.2	9.7	
Gonal-F		135	3.3	13.3	
Estratest		125	3.1	22.6	
Others		1,777	43.8	14.6	
<b>Total</b>		<b>4,057</b>	<b>100.0</b>	<b>11.8</b>	
Zyprexa		1,823	45.4	28.6	
Risperdal		1,188	29.6	23.8	
Seroquel		539	13.4	69.1	
Clozaril		113	2.8	-5.3	
Others		356	8.9	36.5	
<b>Total</b>		<b>4,020</b>	<b>100.0</b>	<b>30.6</b>	
Flovent		738	20.2	13.9	
Flonase		701	19.2	13.3	
Nasonex		513	14.0	30.8	
Advair		126	0.0	0.0	
Others		1,252	34.2	5.6	
<b>Total</b>		<b>3,655</b>	<b>100.0</b>	<b>28.5</b>	
Atenolol*		552	15.6	3.6	
Toprol		490	13.9	38.6	
Terazosin*		288	8.1	0.4	
Coreg		285	8.1	43.2	
Others		1,916	54.3	-7.4	
<b>Total</b>		<b>3,530</b>	<b>100.0</b>	<b>2.6</b>	

	Sales		
Imitrex	173	0.0	
Ultram	697	21.9	15.9
Zomig	209	6.5	9.7
Imitrex	222	0.0	
Others	1,268	39.8	-34.4
<b>Total</b>	<b>3,187</b>	<b>100.0</b>	<b>17.0</b>
Ortho Tri-Cyclen	768	24.1	24.4
Ortho-Novum	196	6.2	-3.7
Alesse 28	183	5.8	6.6
Ortho-Cyclen	176	5.5	11.6
Others	1,859	58.4	10.4
<b>Total</b>	<b>3,182</b>	<b>100.0</b>	<b>12.3</b>
Albuterol	703	23.8	40.2
Serevent	490	16.6	9.1
Albuterol	369	12.5	13.5
Combivent	286	9.7	24.7
Others	1,100	37.3	3.8
<b>Total</b>	<b>2,948</b>	<b>100.0</b>	<b>14.9</b>
Combivir	496	19.3	9.5
Viracept	311	12.1	-1.4
Zerit	288	11.2	8.9
Epivir	220	8.6	7.4
Others	1,257	48.8	40.5
<b>Total</b>	<b>2,572</b>	<b>100.0</b>	<b>20.6</b>
Alprazolam*	599	24.2	22.3
Lorazepam*	537	21.7	1.2
Buspirone	101	0.0	
Buspar	208	8.4	-52.0
Others	819	33.1	-11.3
<b>Total</b>	<b>2,472</b>	<b>100.0</b>	<b>4.0</b>

		Sales			
Lamisil		543	25.1	11.3	
Diflucan		426	19.7	10.0	
Sporanox		213	9.8	-13.0	
Lotrisone		135	6.2	-44.6	
Others		849	39.2	32.5	
<b>Total</b>		<b>2,164</b>	<b>100.0</b>	<b>8.1</b>	
Augmentin		1,873	98.3	18.2	
Augmentin		57	0.0	0.0	
Zosyn		1.0	0.0	21.0	
Unasyn		0.0	0.0	-23.6	
Others		0.0	0.0	5.0	
<b>Total</b>		<b>1,906</b>	<b>100.0</b>	<b>20.2</b>	
Fosamax		1,038	54.6	47.4	MSD
Evista		471	24.8	18.1	
Miacalcin		228	12.0	-7.0	
Actonel		141	7.4	33.3	
Others		24	1.2	-9.7	
<b>Total</b>		<b>1,902</b>	<b>100.0</b>	<b>35.2</b>	
Claritin		571	34.6	15.7	
Claritin		441	26.8	9.5	
Allegra D		390	23.7	25.7	
Rynatan		22	1.3	28.2	
Others		224	13.6	8.7	
<b>Total</b>		<b>1,648</b>	<b>100.0</b>	<b>15.3</b>	
Tamoxifen*		444	29.2	12.8	
Casodex		155	10.2	7.8	
Lupron		127	8.4	8.7	
Megace		87	5.7	-4.1	
Others		708	46.5	24.0	
<b>Total</b>		<b>1,521</b>	<b>100.0</b>	<b>15.6</b>	

	Sales			
Adderall	512	34.3	66.5	
Concerta	370	24.8	620.3	
Provigil	130	8.7	107.1	
Methylphenidate*	129	8.7	-25.2	
Others	350	23.5	-11.0	
<b>Total</b>	<b>1,491</b>	<b>100.0</b>	<b>51.0</b>	
Valtrex	430	29.1	38.1	
Acyclovir*	224	15.2		
Famvir	199	13.5	-3.1	
Rebetron	153	10.4	-19.4	
Others	469	31.8	-36	
<b>Total</b>	<b>1,475</b>	<b>100.0</b>	<b>2.5</b>	
Prednisone	153	10.6	7.6	
Elocon	131	9.1	15.9	
Methylprednisolone	110	7.6	8.1	
Clobetasol*	92	6.4	21.1	
Others	959	66.4	9.7	
<b>Total</b>	<b>1,445</b>	<b>100.0</b>	<b>10.6</b>	
Accutane	628	46.8	-1.3	
Benzamycin	192	14.3	-2.3	
Differin	162	12.1	19.1	
Retin-A	64	4.7	9.5	
Others	297	22.1	25.2	
<b>Total</b>	<b>1,343</b>	<b>100.0</b>	<b>6.2</b>	
Ambien	1,048	79.2	31.2	
Sonata	109	8.3	11.8	
Temazepam*	97	7.3	3.4	
Triazolam*	24	1.8	1.2	
Others	46	3.4	-9.2	
<b>Total</b>	<b>1,323</b>	<b>100.0</b>	<b>24.4</b>	

>>

Analyst	e - mail	Tel
	myungho@deri.co.kr	769 - 3055
	jmj@deri.co.kr	3062
	sanghee@deri.co.kr	3095
	parkjh@deri.co.kr	3102
	sklim@deri.co.kr	3049
	cyw92@deri.co.kr	3076
	tjkim@deri.co.kr	3047
	smkim@deri.co.kr	3071
	jeongup@deri.co.kr	3068
	ksimy@deri.co.kr	3096
	ybjun@deri.co.kr	3048
	shyang@deri.co.kr	3079
	int98@deri.co.kr	3069
	yonghwa@deri.co.kr	3082
	lee0626@deri.co.kr	3022
	lhkang@deri.co.kr	3097
	wkchoi@deri.co.kr	3072
	lyy@deri.co.kr	3087
	kapital@deri.co.kr	3107
	mkkim@deri.co.kr	3027
	youiwe@deri.co.kr	3089
	bekay@deri.co.kr	3036
	bcleee@deri.co.kr	3018

>> Compliance Notice

- 4 - 16 가
- 가 3
- Overweight( ): 6
  - Neutral( ): 6
  - Underweight( ): 6
- Strong Buy : 3 20%p 가 -BUY : 6 10%p 가
  - Marketperform : 6 -10~10%p 가 - Sell : 6 -10%p 가
- 가
  - : BUY/28,500 (02,11,28) BUY/28,500 (02,11,26) BUY/29,900 (02,10,31) BUY/31,700 (02,9,19) BUY/31,100 (02,8,9)
  - : BUY/23,200 (02,11,28) BUY/22,400 (02,11,1)
- 가